- Home
- NTZ vs PRLD Comparison
NTZ vs PRLD Comparison
Compare NTZ & PRLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NTZ
- PRLD
- Stock Information
- Founded
- NTZ 1959
- PRLD 2016
- Country
- NTZ Italy
- PRLD United States
- Employees
- NTZ N/A
- PRLD N/A
- Industry
- NTZ Home Furnishings
- PRLD Medicinal Chemicals and Botanical Products
- Sector
- NTZ Consumer Discretionary
- PRLD Health Care
- Exchange
- NTZ Nasdaq
- PRLD Nasdaq
- Market Cap
- NTZ 49.5M
- PRLD 50.1M
- IPO Year
- NTZ 1993
- PRLD 2020
- Fundamental
- Price
- NTZ $3.25
- PRLD $0.89
- Analyst Decision
- NTZ
- PRLD Strong Buy
- Analyst Count
- NTZ 0
- PRLD 2
- Target Price
- NTZ N/A
- PRLD $4.50
- AVG Volume (30 Days)
- NTZ 4.0K
- PRLD 99.4K
- Earning Date
- NTZ 06-20-2025
- PRLD 05-06-2025
- Dividend Yield
- NTZ N/A
- PRLD N/A
- EPS Growth
- NTZ N/A
- PRLD N/A
- EPS
- NTZ N/A
- PRLD N/A
- Revenue
- NTZ $330,051,765.00
- PRLD $7,000,000.00
- Revenue This Year
- NTZ N/A
- PRLD N/A
- Revenue Next Year
- NTZ N/A
- PRLD N/A
- P/E Ratio
- NTZ N/A
- PRLD N/A
- Revenue Growth
- NTZ N/A
- PRLD N/A
- 52 Week Low
- NTZ $3.07
- PRLD $0.61
- 52 Week High
- NTZ $6.27
- PRLD $6.80
- Technical
- Relative Strength Index (RSI)
- NTZ 33.17
- PRLD 51.43
- Support Level
- NTZ $3.27
- PRLD $0.85
- Resistance Level
- NTZ $3.75
- PRLD $1.00
- Average True Range (ATR)
- NTZ 0.19
- PRLD 0.10
- MACD
- NTZ -0.03
- PRLD -0.00
- Stochastic Oscillator
- NTZ 9.47
- PRLD 44.63
About NTZ Natuzzi S.p.A.
Natuzzi SpA is an Italian firm that designs, manufactures, and sells contemporary and traditional leather and fabric-upholstered furniture. Its product portfolio including sofas, loveseats, armchairs, sectional furniture, motion furniture and sofa beds, living room furnishings, and accessories. The company markets its products under several brands such as Natuzzi Italia, Private label, and Natuzzi Editions. Geographically, it derives a majority of revenue from the United States of America and also has an international presence in Italy, Spain, UK and Other countries.
About PRLD Prelude Therapeutics Incorporated
Prelude Therapeutics Incorp is a clinical stage precision oncology company focused on discovering and developing small molecule therapies optimized to target the key driver mechanisms in cancers with high unmet needs. The company's pipeline includes four candidates currently in clinical development: PRT1419, a potent, selective inhibitor of MCL1; PRT2527, a potent and selective CDK9 inhibitor, PRT3645, a next-generation CDK4/6 inhibitor, and PRT3789 a first-in-class SMARCA2/BRM protein degrader.